EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY-NC 4.0

Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP)

Nam Hoon Kim, Soo Lim, In-Kyung Jeong, Eun-Jung Rhee, Jun Sung Moon, Ohk-Hyun Ryu, Hyuk-Sang Kwon, Jong Chul Won, Sang Soo Kim, Sang Yong Kim, Bon Jeong Ku, Heung Yong Jin und 2 weitere

Diabetes & Metabolism Journal · 2025

DOI: 10.4093/dmj.2024.0238 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes & Metabolism Journal, 2025. Verfasst von Nam Hoon Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seou…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daewoong Pharmaceutical Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor enavogliflozin effectively lowers glycosylated hemoglobin levels and body weights without the increased risk of serious adverse events; however, the long-term clinical benefits of enavogliflozin in terms of cardiovascular and renal outcomes have not been investigated.

Methods

This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults (aged ≥19 years) with type 2 diabetes mellitus (T2DM) who have a history of, or are at risk of, cardiovascular disease. A total of 2,862 participants will be randomly assigned to receive either enavogliflozin or other SGLT2 inhibitors with proven cardiorenal benefits, such as dapagliflozin or empagliflozin. The primary endpoint is the time to the first occurrence of a composite of major adverse cardiovascular or renal events (Clinical Research Information Service registration number: KCT0009243).

Conclusion

This trial will determine whether enavogliflozin is non-inferior to dapagliflozin or empagliflozin in terms of cardiorenal outcomes in patients with T2DM and cardiovascular risk factors. This study will elucidate the role of enavogliflozin in preventing vascular complications in patients with T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsAdultAgedFemaleHumansMaleMiddle AgedBenzhydryl CompoundsGlucosidesGlycated HemoglobinMulticenter Studies as TopicTreatment OutcomeEquivalence Trials as TopicPragmatic Clinical Trials as TopicBenzofurans

Stichwörter der Autor:innen

Cardiovascular diseasesDiabetes mellitus, type 2EnavogliflozinKidney diseasesRandomized controlled trialSodium- glucose transporter 2 inhibitors

Substanzen

6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-tri…Benzhydryl CompoundsEnavogliflozinGlucosidesGlycated HemoglobinSodium-Glucose Transporter 2 InhibitorsBenzofurans

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
  • Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon, Korea.

Förderung

  • Daewoong Pharmaceutical Co. Ltd.

Zitieren

APA

Kim, N. H., Lim, S., Jeong, I. K., Rhee, E. J., Moon, J. S., Ryu, O. H., Kwon, H. S., Won, J. C., Kim, S. S., Kim, S. Y., Ku, B. J., Jin, H. Y., Kim, S. G., & Cha, B. S. (2025). Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP). Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2024.0238

Vancouver

Kim NH, Lim S, Jeong IK, Rhee EJ, Moon JS, Ryu OH, et al. Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP). Diabetes & Metabolism Journal. 2025. doi:10.4093/dmj.2024.0238

BibTeX
@article{Kim2025,
  author = {Kim, Nam Hoon and Lim, Soo and Jeong, In-Kyung and Rhee, Eun-Jung and Moon, Jun Sung and Ryu, Ohk-Hyun and Kwon, Hyuk-Sang and Won, Jong Chul and Kim, Sang Soo and Kim, Sang Yong and Ku, Bon Jeong and Jin, Heung Yong and Kim, Sin Gon and Cha, Bong-Soo},
  title = {Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP)},
  journal = {Diabetes & Metabolism Journal},
  year = {2025},
  doi = {10.4093/dmj.2024.0238}
}
Kostenlos starten →